These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 37330601)
1. CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas. Baur K; Buser A; Jeker LT; Khanna N; Läubli H; Heim D; Dirks JC; Widmer CC; Volken T; Passweg JR; Holbro A Bone Marrow Transplant; 2023 Sep; 58(9):1048-1050. PubMed ID: 37330601 [No Abstract] [Full Text] [Related]
2. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. Strati P; Neelapu SS Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158 [TBL] [Abstract][Full Text] [Related]
3. [How I manage B cell lymphoma patients treated with CD19 specific CAR-T cell throughout whole-process management]. Qian WB; Liu H Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):197-202. PubMed ID: 35405776 [No Abstract] [Full Text] [Related]
4. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. Levin A; Shah NN Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353 [TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art. Abramson JS; Lunning M; Palomba ML Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671 [TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Chen G; Herr M; Nowak J; Ho C; Almyroudis N; Attwood K; Bonnewell J; Walsh M; Segal B; Ross M; McCarthy P; Hahn T Haematologica; 2023 Feb; 108(2):615-620. PubMed ID: 36263844 [No Abstract] [Full Text] [Related]
7. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474 [TBL] [Abstract][Full Text] [Related]
8. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452 [TBL] [Abstract][Full Text] [Related]
9. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas. Sharma P; King GT; Shinde SS; Purev E; Jimeno A Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253 [TBL] [Abstract][Full Text] [Related]
10. CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas. Fitzgerald KN; Quesada AE; von Keudell G; Raj S; Lewis NE; Dogan A; Salles G; Palomba ML Leuk Lymphoma; 2022 Mar; 63(3):751-754. PubMed ID: 34949132 [No Abstract] [Full Text] [Related]
11. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Srour SA; Singh H; McCarty J; de Groot E; Huls H; Rondon G; Qazilbash M; Ciurea S; Bardelli G; Buck J; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Wierda WG; Kantarjian H; Champlin RE; Cooper LJ; Kebriaei P Blood; 2020 Mar; 135(11):862-865. PubMed ID: 31961918 [No Abstract] [Full Text] [Related]
12. Impact of Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572 [TBL] [Abstract][Full Text] [Related]